Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cozart gets RapiScan vote of confidence in UK, expands overseas

This article was originally published in Clinica

Executive Summary

The pace of business for UK immunodiagnostics company Cozart Bioscience is hotting up. The Abingdon-based company is planning a worldwide launch (except US) of its sensitive on-site RapiScan test for detecting buprenorphine use and nor- buprenorphine in urine. The analgesic is used as an alternative to methadone in moving patients off heroine and opiates, and the kit will be a useful tool helping staff in drug dependency clinics to check rapidly - within ten minutes - if patients are complying with their treatment regimes. The launch will take place next month.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts